Bank of Montreal’s Viridian Therapeutics VRDN Stock Holding History

Bank of Montreal’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-23,000	Closed	-$414K	–	4480
2022 Q1	$414K	Buy	+23,000	New	+$442K	﹤0.01%	2975
2019 Q3	–	Sell	-404	Closed	-$12K	–	5009
2019 Q2	$12K	Buy	404 +324	+405%	+$13K	﹤0.01%	4453
2019 Q1	$3K	Sell	80 -24	-23%	-$1.09K	﹤0.01%	4114
2018 Q4	$5K	Buy	104 +92	+767%	+$5.32K	﹤0.01%	4106
2018 Q3	$1K	Hold	12	–	–	﹤0.01%	4610
2018 Q2	$1K	Buy	+12	New	+$1.27K	﹤0.01%	4598

Other funds holding VRDN

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of Montreal's VRDN Position: Q2 2022 in Review

Bank of Montreal sold out of Viridian Therapeutics (VRDN) in Q2 2022, closing a stake of 23,000 shares — an estimated $414K sold.

Bank of Montreal first reported a position in VRDN in Q2 2018 and held it in 6 quarters. The position peaked at $414K in Q1 2022. 84 funds tracked by Wall St. Rank hold VRDN as of Q2 2022.

Bank of Montreal reported no remaining Viridian Therapeutics position as of Q2 2022 after selling out during the quarter.
Bank of Montreal sold 23,000 Viridian Therapeutics shares in Q2 2022, an estimated $414K.
Bank of Montreal first reported a position in Viridian Therapeutics in Q2 2018 and held it in 6 quarters.
Bank of Montreal's Viridian Therapeutics position peaked at $414K in Q1 2022.
84 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2022.

Based on Bank of Montreal's 13F filing for Q2 2022, filed 11 Aug 2022.